RBC Capital analyst Randall Stanicky says that the take-out valuation of drug companies have recently dropped to the historical level of 12 times EBITDA, while Akorn's take-out valuation may be "modestly lower" given the "depressed valuation" of the "generic sector." Consequently, after Bloomberg reported that Fresenius is in talks to acquire Akorn, and Akorn's stock jumped, Stanicky believes that the shares, which have reached 13 times EBITDA in pre=market trading, are fully valued. He does not see another "obvious" buyer for Akorn and keeps a Sector Perform rating on the shares.